APX3330: A Clinically Staged Non-Invasive Oral Therapy for Diabetic Retinopathy

Time: 10:00 am
day: Conference Day 1


  • Phase 2 clinical trial results in a placebo-controlled trial showing promising therapeutic potential
  • Discussing the biology of Ref-1 and inhibition using APX3330, a first in class agent
  • Exploring the promise of DR clinical trials with an oral therapy